JP2015523397A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015523397A5 JP2015523397A5 JP2015524444A JP2015524444A JP2015523397A5 JP 2015523397 A5 JP2015523397 A5 JP 2015523397A5 JP 2015524444 A JP2015524444 A JP 2015524444A JP 2015524444 A JP2015524444 A JP 2015524444A JP 2015523397 A5 JP2015523397 A5 JP 2015523397A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- combination
- proliferative
- inhibitor
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 230000002062 proliferating effect Effects 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 15
- 206010009944 Colon cancer Diseases 0.000 claims description 10
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 8
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 8
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 claims description 6
- 101100381978 Mus musculus Braf gene Proteins 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 claims description 4
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 229940124647 MEK inhibitor Drugs 0.000 claims description 4
- 208000009905 Neurofibromatoses Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000004931 neurofibromatosis Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 description 6
- 0 CC(C)[n](cc1-c2nc(NC[C@](C)NC(OC)=O)ncc2)nc1-c1cc(Cl)cc([n]2)c1*s2(C)=O Chemical compound CC(C)[n](cc1-c2nc(NC[C@](C)NC(OC)=O)ncc2)nc1-c1cc(Cl)cc([n]2)c1*s2(C)=O 0.000 description 1
- RHXHGRAEPCAFML-UHFFFAOYSA-N CN(C)C(c1cc2cnc(Nc(cc3)ncc3N3CCNCC3)nc2[n]1C1CCCC1)=O Chemical compound CN(C)C(c1cc2cnc(Nc(cc3)ncc3N3CCNCC3)nc2[n]1C1CCCC1)=O RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261676134P | 2012-07-26 | 2012-07-26 | |
| US61/676,134 | 2012-07-26 | ||
| US201361830911P | 2013-06-04 | 2013-06-04 | |
| US61/830,911 | 2013-06-04 | ||
| PCT/US2013/051990 WO2014018725A1 (en) | 2012-07-26 | 2013-07-25 | Pharmaceutical combinations of a cdk4/6 inhibitor and a b-raf inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015523397A JP2015523397A (ja) | 2015-08-13 |
| JP2015523397A5 true JP2015523397A5 (enExample) | 2016-08-25 |
| JP6320379B2 JP6320379B2 (ja) | 2018-05-09 |
Family
ID=48917729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015524444A Active JP6320379B2 (ja) | 2012-07-26 | 2013-07-25 | Ｃｄｋ４／６阻害剤およびｂ−ｒａｆ阻害剤の組合せ医薬 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9700557B2 (enExample) |
| EP (1) | EP2877174B1 (enExample) |
| JP (1) | JP6320379B2 (enExample) |
| KR (1) | KR102113363B1 (enExample) |
| CN (1) | CN104507474B (enExample) |
| AR (1) | AR091876A1 (enExample) |
| AU (1) | AU2013295771B2 (enExample) |
| CA (1) | CA2874860C (enExample) |
| ES (1) | ES2778059T3 (enExample) |
| IN (1) | IN2015DN00376A (enExample) |
| JO (1) | JO3776B1 (enExample) |
| MX (1) | MX360045B (enExample) |
| RU (1) | RU2685250C2 (enExample) |
| TW (1) | TWI599357B (enExample) |
| WO (1) | WO2014018725A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9867825B2 (en) * | 2012-12-20 | 2018-01-16 | Novartis Ag | Pharmaceutical combination comprising binimetinib |
| EP3327144B1 (en) * | 2013-02-25 | 2020-03-25 | Novartis AG | Novel androgen receptor mutation |
| CA2907704C (en) * | 2013-03-21 | 2023-01-10 | Giordano Caponigro | Combination therapy for reversing b-raf inhibitor resistance comprising a second inhibitor based on genetic alterations |
| CA2972076A1 (en) * | 2014-12-23 | 2016-06-30 | Millennium Pharmaceuticals, Inc. | Combination of raf inhibitors and aurora kinase inhibitors |
| CN105753869B (zh) * | 2015-04-01 | 2018-09-25 | 苏州晶云药物科技有限公司 | 一种cdk抑制剂和mek抑制剂的共晶及其制备方法 |
| US10323035B2 (en) * | 2015-04-01 | 2019-06-18 | Crystal Pharmatech Co., Ltd. | Co-crystal of a CDK inhibitor and an MEK inhibitor and process of preparation thereof |
| WO2017037574A1 (en) * | 2015-08-28 | 2017-03-09 | Novartis Ag | Combinations of the cdk4/6 inhibitor lee011 and the mek1/2 inhibitor trametinib, optionally further comprising the pi3k inhibitor byl719 to treat cancer |
| CN105732642B (zh) * | 2015-11-18 | 2018-09-25 | 苏州晶云药物科技有限公司 | 一种cdk抑制剂和mek抑制剂的共晶及其制备方法 |
| UA125436C2 (uk) * | 2016-06-03 | 2022-03-09 | Еррей Біофарма, Інк. | Фармацевтичні комбінації |
| AU2017315357B2 (en) * | 2016-08-23 | 2022-12-01 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of hepatocellular carcinoma |
| KR102341660B1 (ko) | 2016-09-19 | 2021-12-23 | 노파르티스 아게 | Raf 억제제 및 erk 억제제를 포함하는 치료적 조합 |
| WO2018081211A1 (en) * | 2016-10-26 | 2018-05-03 | Li George Y | Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide |
| US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
| ES2952265T3 (es) | 2017-05-02 | 2023-10-30 | Novartis Ag | Terapia combinada que comprende un inhibidor de Raf y trametinib |
| WO2018218633A1 (en) | 2017-06-02 | 2018-12-06 | Beijing Percans Oncology Co. Ltd. | Combination therapies for treating cancers |
| PE20210121A1 (es) | 2018-01-08 | 2021-01-19 | G1 Therapeutics Inc | Regimenes de dosificacion superior de g1t38 |
| CA3089592A1 (en) | 2018-02-15 | 2019-08-22 | Nuvation Bio Inc. | Heterocyclic compounds as kinase inhibitors |
| WO2019195959A1 (en) * | 2018-04-08 | 2019-10-17 | Cothera Biosciences, Inc. | Combination therapy for cancers with braf mutation |
| US11633401B2 (en) * | 2018-07-06 | 2023-04-25 | Memorial Sloan Kettering Cancer Center | Combination therapy with MEK inhibitor and CDK4/6 inhibitor to treat pancreatic cancer |
| MX2021007477A (es) * | 2018-12-20 | 2021-08-05 | Novartis Ag | Terapia de combinacion con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cancer. |
| EP3969449B1 (en) | 2019-05-13 | 2025-02-12 | Novartis AG | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer |
| TW202114667A (zh) * | 2019-09-11 | 2021-04-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | Mek抑制劑與cdk4/6抑制劑聯合在製備治療腫瘤的藥物中的用途 |
| IL292161B2 (en) | 2019-12-10 | 2025-04-01 | Hoffmann La Roche | New methylquinazolinone derivatives |
| US20240000789A1 (en) * | 2020-05-12 | 2024-01-04 | Novartis Ag | Therapeutic combinations comprising a craf inhibitor |
| WO2023230554A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer |
| WO2025003956A1 (en) | 2023-06-30 | 2025-01-02 | Pfizer Inc. | High drug loading formulations of encorafenib |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL401638A1 (pl) * | 2002-03-13 | 2013-05-27 | Array Biopharma Inc. | N3 alkilowane pochodne benzimidazolu jako inhibitory MEK |
| US7235537B2 (en) * | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| WO2005094830A1 (en) * | 2004-03-30 | 2005-10-13 | Pfizer Products Inc. | Combinations of signal transduction inhibitors |
| MX2011000440A (es) | 2008-07-11 | 2011-02-24 | Novartis Ag | Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek. |
| NZ591176A (en) | 2008-08-22 | 2012-11-30 | Novartis Ag | Pyrrolopyrimidine compounds as cdk inhibitors |
| AR077975A1 (es) * | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
| ES2689177T3 (es) | 2010-04-13 | 2018-11-08 | Novartis Ag | Combinación que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (CDK4/6) y un inhibidor de mTOR para tratar cáncer |
-
2013
- 2013-07-24 AR ARP130102621A patent/AR091876A1/es not_active Application Discontinuation
- 2013-07-25 WO PCT/US2013/051990 patent/WO2014018725A1/en not_active Ceased
- 2013-07-25 AU AU2013295771A patent/AU2013295771B2/en active Active
- 2013-07-25 EP EP13745540.8A patent/EP2877174B1/en active Active
- 2013-07-25 CN CN201380039725.5A patent/CN104507474B/zh active Active
- 2013-07-25 MX MX2015001122A patent/MX360045B/es active IP Right Grant
- 2013-07-25 RU RU2015106524A patent/RU2685250C2/ru active
- 2013-07-25 IN IN376DEN2015 patent/IN2015DN00376A/en unknown
- 2013-07-25 JP JP2015524444A patent/JP6320379B2/ja active Active
- 2013-07-25 CA CA2874860A patent/CA2874860C/en active Active
- 2013-07-25 ES ES13745540T patent/ES2778059T3/es active Active
- 2013-07-25 US US14/414,998 patent/US9700557B2/en active Active
- 2013-07-25 TW TW102126726A patent/TWI599357B/zh active
- 2013-07-25 JO JOP/2013/0223A patent/JO3776B1/ar active
- 2013-07-25 KR KR1020157001594A patent/KR102113363B1/ko active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015523397A5 (enExample) | ||
| RU2015106524A (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ ИНГИБИТОРА CDK4/6 И ИНГИБИТОРА В-Raf | |
| JP2015536964A5 (enExample) | ||
| RU2015121367A (ru) | Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний | |
| JP2018109022A5 (enExample) | ||
| JP2022009090A5 (enExample) | ||
| JP2018526376A5 (enExample) | ||
| JP2017504611A5 (enExample) | ||
| JP2014509659A5 (enExample) | ||
| JP2013522212A5 (enExample) | ||
| JP2015528491A5 (enExample) | ||
| JP2016515628A5 (enExample) | ||
| RU2012153963A (ru) | Лечение рака груди с помощью соединения 4-иод-3-нитробензамид в комбинации с противоопухолевыми средствами | |
| JP2016501221A5 (enExample) | ||
| JP2013507415A5 (enExample) | ||
| JP2015529234A5 (enExample) | ||
| JP2013522326A5 (enExample) | ||
| RU2014144254A (ru) | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение | |
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2019511526A5 (enExample) | ||
| JP2014525454A5 (enExample) | ||
| JP2015503596A5 (enExample) | ||
| JP2014533272A5 (enExample) | ||
| RU2016110874A (ru) | Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний | |
| JP2014512355A5 (enExample) |